APTX - Aptinyx shares fell 3% despite positive NYX-783 data in PTSD

Aptinyx (APTX) presents additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder ((PTSD)). The study, enrolling 153 patients, consisted of two four-week treatment stages comparing once-daily oral dosing of NYX-783—10mg or 50mg—to placebo.A significantly greater proportion (p<0.05) of patients achieved a Clinically Reliable Change (improvement of ?13 points on the CAPS-5 Total score) in 50 mg treatment group compared to placebo.Percentage improvement on the CAPS-5 Total score for the NYX-783 50 mg group was significant (p<0.05 vs. placebo) when adjusting for variances in patients’ time since trauma. On the CAPS-5 symptom cluster scores, improvements on Arousal and Reactivity and Negative Cognitions and Mood were significant for the 50 mg QD group (all p<0.05).Improvement on the HADS-Anxiety scale was statistically significant for the 10 and 50 mg groups.NYX-783 was well-tolerated compared to placebo and there were no drug-related serious adverse events.The data were presented

For further details see:

Aptinyx shares fell 3% despite positive NYX-783 data in PTSD